Indivior PLC (INDV)
NMS – Real vaqt narxi. Valyuta: USD
38.15
-0.28 (-0.73%)
Bozor ochiq: Aug 12, 2026, 2:35 PM EDT
38.43
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
38.15
-0.28 (-0.73%)
Bozor ochiq: Aug 12, 2026, 2:35 PM EDT
38.43
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Indivior PLC, sho'ba korxonalari bilan birgalikda, Qo'shma Shtatlar, Evropa, Kanada, Avstraliya va xalqaro miqyosda opiatga qaramlik va tegishli buzilishlarni davolash uchun buprenorfin asosidagi retsept bo'yicha dori vositalarini ishlab chiqadi, ishlab chiqaradi va sotadi. Kompaniya modda bilan bog'liq buzilishlarni davolash uchun dori vositalarini ishlab chiqadi. Uning asosiy sotiladigan mahsulotlariga SUBLOCADE buprenorfin uzoq muddatli oylik in'ektsiyalari; SUBOXONE Film, buprenorfin va naloksonni o'z ichiga olgan sublingual plyonka; SUBOXONE Tablet, buprenorfin va naloksonni o'z ichiga olgan sublingual tabletka; va SUBUTEX Tablet, opiatdan foydalanish buzilishini (OUD) davolash uchun buprenorfin sublingual tabletkasi kiradi. Kompaniya, shuningdek, opiatning haddan tashqari dozalashini qaytarish uchun OPVEE burun spreyini taklif etadi. Bundan tashqari, u o'rtacha va og'ir OUDni davolash uchun 2-bosqichli klinik sinovda bo'lgan selektiv oreksin-1 retseptorlari antagonistini INDV-2000; va Alar Pharmaceuticals Inc bilan hamkorlikda OUDni davolash uchun buprenorfin asosidagi uzoq muddatli in'ektsion preparatni INDV-6001 ishlab chiqmoqda. Indivior PLC 2014 yilda tashkil etilgan va uning bosh qarorgohi Shimoliy Chesterfild, Virjiniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ann Wheeler Pharm.D. | Chief Medical Officer |
| Dr. Christian Heidbreder | Chief Scientific Officer |
| Mr. Jason Thompson | Vice President of Investor Relations |
| Mr. Jeffrey W. Burris J.D. | Chief Legal Officer |
| Mr. Joseph J. Ciaffoni | CEO & Director |
| Mr. Kevin L. Espinoza | Chief Integrity & Compliance Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-03 | 425 | d118566d425.htm |
| 2026-08-03 | 10-Q | indv-20260630.htm |
| 2026-05-15 | 8-K | indv-20260513.htm |
| 2026-05-04 | 8-K | indv-20260504.htm |
| 2026-04-30 | 8-K | d40828d8k.htm |
| 2026-04-30 | 10-Q | indv-20260331.htm |
| 2026-03-27 | DEFA14A | tm267639d3_defa14a.htm |
| 2026-03-27 | DEF 14A | tm267639d1_def14a.htm |
| 2026-03-27 | ARS | tm267635d2_ars.pdf |
| 2026-03-17 | 8-K | indv-20260317.htm |
| Mr. Patrick a. Barry | Chief Commercial Officer |
| Mr. Ryan Preblick | Chief Financial Officer |
| Ms. Angela Colon-Mahoney M.S. | Chief Human Resources Officer |
| Ms. Vanessa Procter | Executive Vice President of Corporate Affairs |